Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients.

Liver disease is common among patients infected with HIV. The proportion of deaths caused by liver-related aetiologies has increased between 8 to 10-fold in the post-antiretroviral therapy (ART) era while AIDS-related mortality has fallen more than 90-fold. NAFLD is an important contributor to this trend. Higher rates of the...
PUBLISHED IN: AIDS. 2020

Commentary

Liver disease is common among patients infected with HIV. The proportion of deaths caused by liver-related aetiologies has increased between 8 to 10-fold in the post-antiretroviral therapy (ART) era while AIDS-related mortality has fallen more than 90-fold.

NAFLD is an important contributor to this trend. Higher rates of the disease are reported in HIV-infected patients, ranging from 7.3% to 57.1%. This is likely due to both high frequency of metabolic conditions underlying the pathogenesis of NASH and ART-related hepatotoxicity.

Despite the disease burden, there are no proven treatments to reduce HIV-associated NASH. Vitamin E treatment seems safe and leads to rapid and sustained normalization of Alanine aminotransferase and reduction of hepatic steatosis in a significant number of HIV mono-infected patients with a non-invasive diagnosis of NASH.

Share the article
Dr. D. Beard

Dr. D. Beard

Articles: 190

Leave a Reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES